The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting & Pre-Conference Programs (SITC 2022) are taking place Nov. 8–12, 2022, at the Boston Convention and Exhibition Center in Boston. BBCR will be attending the conference this week and is looking forward to reporting back on conference events. Are you attending? Please let us know! […]
Tagged: SITC
BBCR is attending this week’s SITC 37th Annual Meeting & Pre-Conference Program and we will reporting on conference events soon.
November 9th, 2022 | SITCCategories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- BBCR and its consultants are dedicated to advancing innovative and repurposed treatments for orphan diseases, an area where impact is high, but the path is complex.
- BBCR’s mission is to support domestic and international pharma, biotech, and device companies by nurturing their products’ strengths, while improving efficiency and safety. We specialize in strategy and provide early clinical research services to enable informed, timely decision-making for our clients.
- BBCR brings deep expertise in early-stage development, including Phase 1 and Phase 2 process and strategy, spanning pre-clinical work through pre-IND. Our early drug development capabilities encompass clinical strategy and planning, including the creation of target product profiles and the design of clinical protocols.
- BBCR partners with clients to identify, develop, and advance a product’s unique strengths from early concept through to market. Our consultancy is grounded in deep expertise across cell, biologic, and gene therapies, with a particular focus on rare disease.
- BBCR’s team of experts help clients match treatments to rare genetic conditions and unsolved diseases, then work collaboratively with a product developer on the best plan to market. To learn more, visit bbcrconsulting.com.